With a foundation built upon initial work from the 1980s demonstrating graft viability in cerebral ischemia, stem cell transplantation has shown immense promise in promoting survival, enhancing neuroprotection and inducing neuroregeneration, while mitigating both histological and behavioral deficits that frequently accompany ischemic stroke. These findings have led to a number of clinical trials that have thoroughly supported a strong safety profile for stem cell therapy in patients but have generated variable efficacy. As preclinical evidence continues to expand through the investigation of new cell lines and optimization of stem cell delivery, it remains critical for translational models to adhere to the protocols established through basic scientific research. With the recent shift in approach towards utilization of stem cells as a conjunctive therapy alongside standard thrombolytic treatments, key issues including timing, route of administration, and stem cell type must each be appropriately translated from the laboratory in order to resolve the question of stem cell efficacy for cerebral ischemia that ultimately will enhance therapeutics for stroke patients towards improving quality of life.
MampalamTJGonzalezMFWeinsteinP, et al.
Neuronal changes in fetal cortex transplanted to ischemic adult rat cortex. J Neurosurg1988;
69: 904–912.
2.
SharpFR.Transplants for stroke patients?Ann Neurol1993;
34: 322–323.
3.
GrabowskiMBrundinPJohanssonBB.Fetal neocortical grafts implanted in adult hypertensive rats with cortical infarcts following a middle cerebral artery occlusion: ingrowth of afferent fibers from the host brain. Exp Neurol1992;
116: 105–121.
4.
GrabowskiMChristoffersonRHBrundinP, et al.
Vascularization of fetal neocortical grafts implanted in brain infarcts in spontaneously hypertensive rats. Neuroscience1992;
51: 673–682.
5.
GrabowskiMBrundinPJohanssonBB.Functional integration of cortical grafts placed in brain infarcts of rats. Ann Neurol1993;
34: 362–368.
6.
NishinoHAiharaNCzurkoA, et al.
Reconstruction of GABAergic transmission and behavior by striatal cell grafts in rats with ischemic infarcts in the middle cerebral artery. J Neural Transplant Plast1993;
4: 147–155.
7.
AiharaNMizukawaKKoideK, et al.
Striatal grafts in infarct striatopallidum increase GABA release, reorganize GABAA receptor and improve water-maze learning in the rat. Brain Res Bull1994;
33: 483–488.
8.
BorlonganCVKoutouzisTKJordenJR, et al.
Neural transplantation as an experimental treatment modality for cerebral ischemia. Neurosci Biobehav Rev1997;
21: 79–90.
9.
BlissTGuzmanRDaadiM, et al.
Cell transplantation therapy for stroke. Stroke2007;
38: 817–826.
10.
LiuXYeRYanT, et al.
Cell based therapies for ischemic stroke: from basic science to bedside. Prog Neurobiol2014;
115: 92–115.
11.
ZhangRZhangZChoppM.Function of neural stem cells in ischemic brain repair processes. J Cereb Blood Flow Metab2016;
36: 2034–2043.
12.
StonesiferCCoreySGhanekarS, et al.
Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms. Prog Neurobiol2017;
158: 94–131.
13.
BorlonganCVTajimaYTrojanowskiJQ, et al.
Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats. Exp Neurol1998;
149: 310–321.
14.
IkedaRKurokawaMSChibaS, et al.
Transplantation of neural cells derived from retinoic acid-treated cynomolgus monkey embryonic stem cells successfully improved motor function of hemiplegic mice with experimental brain injury. Neurobiol Dis2005;
20: 38–48.
15.
DezawaMKannoHHoshinoM, et al.
Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest2004;
113: 1701–1710.
16.
VirleyDRidleyRMSindenJD, et al.
Primary CA1 and conditionally immortal MHP36 cell grafts restore conditional discrimination learning and recall in marmosets after excitotoxic lesions of the hippocampal CA1 field. Brain1999;
122 (Pt 12): 2321–2335.
17.
LoEHBroderickJPMoskowitzMA.tPA and proteolysis in the neurovascular unit. Stroke2004;
35: 354–356.
18.
VenkatPChoppMChenJ.Cell-based and exosome therapy in diabetic stroke. Stem Cells Transl Med2018;
7: 451–455.
19.
KhoshnamSEWinlowWFarzanehM, et al.
Pathogenic mechanisms following ischemic stroke. Neurol Sci2017;
38: 1167–1186.
20.
BorlonganCVNguyenHLippertT, et al.
May the force be with you: Transfer of healthy mitochondria from stem cells to stroke cells. J Cereb Blood Flow Metab2019;
39: 367–370.
DoeppnerTRHerzJGörgensA, et al.
Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression. Stem Cells Transl Med2015;
4: 1131–1143.
23.
Kikuchi-TauraAOkinakaYTakeuchiY, et al.
Bone marrow mononuclear cells activate angiogenesis via gap junction-mediated cell-cell interaction. Stroke2020;
51: 1279–1289.
24.
XuKLeeJYKanekoY, et al.
Human stem cells transplanted into the rat stroke brain migrate to the spleen via lymphatic and inflammation pathways. Haematologica2019;
104: 1062–1073.
25.
BorlonganCV.Concise review: Stem cell therapy for stroke patients: are we there yet?Stem Cells Transl Med2019;
8: 983–988.
26.
KondziolkaDWechslerLGoldsteinS, et al.
Transplantation of cultured human neuronal cells for patients with stroke. Neurology2000;
55: 565–569.
27.
BatemanMEStrongALGimbleJM, et al.
Concise review: using fat to fight disease: a systematic review of nonhomologous adipose-derived stromal/stem cell therapies. Stem Cells2018;
36: 1311–1328.
28.
NapoliEBorlonganCV.Stem cell recipes of bone marrow and fish: just what the stroke doctors ordered. Stem Cell Rev Rep2017;
13: 192–197.
29.
SunJMKurtzbergJ.Cord blood for brain injury. Cytotherapy2015;
17: 775–785.
30.
IshiiTEtoK.Fetal stem cell transplantation: past, present, and future. World J Stem Cells2014;
6: 404–420.
31.
NapoliELippertTBorlonganCV.Stem cell therapy: Repurposing cell-based regenerative medicine beyond cell replacement. Adv Exp Med Biol2018;
1079: 87–91.
32.
NapoliEBorlonganCV.Recent advances in stem cell-based therapeutics for stroke. Transl Stroke Res2016;
7: 452–457.
33.
BorlonganCV.Age of PISCES: Stem-cell clinical trials in stroke. Lancet2016;
388: 736–738.
34.
BorlonganCV.Preliminary reports of stereotaxic stem cell transplants in chronic stroke patients. Mol Ther2016;
24: 1710–1711.
35.
TangYYasuharaTHaraK, et al.
Transplantation of bone marrow-derived stem cells: a promising therapy for stroke. Cell Transplant2007;
16: 159–169.
36.
GnecchiMMeloLG.Bone marrow-derived mesenchymal stem cells: Isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol2009;
482: 281–294.
37.
LiYFRenLNGuoG, et al.
Endothelial progenitor cells in ischemic stroke: an exploration from hypothesis to therapy. J Hematol Oncol2015;
8: 33.
38.
YasuharaTMatsukawaNHaraK, et al.
Notch-induced rat and human bone marrow stromal cell grafts reduce ischemic cell loss and ameliorate behavioral deficits in chronic stroke animals. Stem Cells Dev2009;
18: 1501–1514.
39.
YasuharaTHaraKMakiM, et al.
Intravenous grafts recapitulate the neurorestoration afforded by intracerebrally delivered multipotent adult progenitor cells in neonatal hypoxic-ischemic rats. J Cereb Blood Flow Metab2008;
28: 1804–1810.
40.
UchidaHMoritaTNiizumaK, et al.
Transplantation of unique subpopulation of fibroblasts, muse cells, ameliorates experimental stroke possibly via robust neuronal differentiation. Stem Cells2016;
34: 160–173.
41.
BorlonganCVGloverLETajiriN, et al.
The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders. Prog Neurobiol2011;
95: 213–228.
42.
BorlonganCV.Bone marrow stem cell mobilization in stroke: a ‘bonehead’ may be good after all!. Leukemia2011;
25: 1674–1686.
43.
RowartPErpicumPDetryO, et al.
Mesenchymal stromal cell therapy in ischemia/reperfusion injury. J Immunol Res2015;
2015: 602597.
44.
EckertMAVuQXieK, et al.
Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke. J Cereb Blood Flow Metab2013;
33: 1322–1334.
JoyceNAnnettGWirthlinL, et al.
Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med2010;
5: 933–946.
47.
van VelthovenCTGonzalezFVexlerZS, et al.
Stem cells for neonatal stroke- the future is here. Front Cell Neurosci2014;
8: 207.
48.
BangOYLeeJSLeePH, et al.
Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol2005;
57: 874–882.
49.
SavitzSIMisraVKasamM, et al.
Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol2011;
70: 59–69.
50.
BanerjeeSBentleyPHamadyM, et al.
Intra-arterial immunoselected CD34+ stem cells for acute ischemic stroke. Stem Cells Transl Med2014;
3: 1322–1330.
51.
PrasadKSharmaAGargA, InveST Study Groupet al.
Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke2014;
45: 3618–3624.
52.
HessDCWechslerLRClarkWM, et al.
Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol2017;
16: 360–368.
53.
SteinbergGKKondziolkaDWechslerLR, et al.
Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study. J Neurosurg2018;
131: 1462–1472.
54.
SteinbergGKKondziolkaDWechslerLR, et al.
Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. Stroke2016;
47: 1817–1824.
55.
LtdSC. SanBio and Sumitomo Dainippon Pharma announce topline results from a phase 2b study in the U.S. evaluating SB623, a regenerative cell medicine for the treatment of patients with chronic stroke, https://www.ds‐pharma.com/ir/news/pdf/ene20190129.1.pdf (2019, accessed 24 April 2023).
56.
DiamandisTBorlonganCV.One, two, three steps toward cell therapy for stroke. Stroke2015;
46: 588–591.
57.
NairABJacobS.A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm2016;
7: 27–31.
58.
KenmuirCLWechslerLR.Update on cell therapy for stroke. Stroke Vasc Neurol2017;
2: 59–64.
MaysRWBorlonganCVYasuharaT, et al.
Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke. J Exp Stroke Transl Med2010;
3: 34–46.
61.
U.S. National Library of Medicine. MultiStem® Administration for Stroke Treament and Enhanced Revocery Study (MASTERS-2), https://clinicaltrials.gov/ct2/show/NCT03545607 (accessed 24 April 2023).
62.
DoeppnerTRHermannDM.Mesenchymal stem cells in the treatment of ischemic stroke: progress and possibilities. Stem Cells Cloning2010;
3: 157–163.
63.
AndersonJDJohanssonHJGrahamCS, et al.
Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappaB signaling. Stem Cells2016;
34: 601–613.
64.
DuffyGPAhsanTO’BrienT, et al.
Bone marrow-derived mesenchymal stem cells promote angiogenic processes in a time- and dose-dependent manner in vitro. Tissue Eng Part A2009;
15: 2459–2470.
65.
XiongYMahmoodAChoppM.Angiogenesis, neurogenesis and brain recovery of function following injury. Curr Opin Investig Drugs2010;
11: 298–308.
66.
IshikawaHTajiriNShinozukaK, et al.
Vasculogenesis in experimental stroke after human cerebral endothelial cell transplantation. Stroke2013;
44: 3473–3481.
PuyalJGinetVClarkePG.Multiple interacting cell death mechanisms in the mediation of excitotoxicity and ischemic brain damage: a challenge for neuroprotection. Prog Neurobiol2013;
105: 24–48.
69.
SozmenEGHinmanJDCarmichaelST.Models that matter: white matter stroke models. Neurotherapeutics2012;
9: 349–358.
70.
Incontri AbrahamDGonzalesMIbarraA, et al.
Stand alone or join forces? Stem cell therapy for stroke. Expert Opin Biol Ther2019;
19: 25–33.
71.
PolgarSBorlonganCVKoutouzisTK, et al.
Implications of neurological rehabilitation for advancing intracerebral transplantation. Brain Res Bull1997;
44: 229–232.
72.
BorlonganCVJolkkonenJDetanteO.The future of stem cell therapy for stroke rehabilitation. Future Neurol2015;
10: 313–319.
73.
LiebeskindDSDerdeynCPWechslerLR.STAIR X: emerging considerations in developing and evaluating new stroke therapies. Stroke2018;
49: 2241–2247.
74.
NguyenHZarrielloSRajaniM, et al.
Understanding the role of dysfunctional and healthy mitochondria in stroke pathology and its treatment. Int J Mol Sci2018;
19.
75.
LabriolaNRAzaguryAGutierrezR, et al.
Concise review: Fabrication, customization, and application of cell mimicking microparticles in stem cell science. Stem Cells Transl Med2018;
7: 232–240.
76.
LamannaJJGutierrezJUrquiaLN, et al.
Ferumoxytol labeling of human neural progenitor cells for diagnostic cellular tracking in the porcine spinal cord with magnetic resonance imaging. Stem Cells Transl Med2017;
6: 139–150.
77.
ChenBLiQZhaoB, et al.
Stem cell-derived extracellular vesicles as a novel potential therapeutic tool for tissue repair. Stem Cells Transl Med2017;
6: 1753–1758.
78.
CrowD.From cell stem cell to clinical trials: the biotech journey of two papers. Cell Stem Cell2017;
20: 746–748.
79.
HuntCJ.Cryopreservation of human stem cells for clinical application: a review. Transfus Med Hemother2011;
38: 107–123.
80.
MenardCPacelliLBassiG, et al.
Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev2013;
22: 1789–1801.
81.
KawaboriMShichinoheHKurodaS, et al.
Clinical trials of stem cell therapy for cerebral ischemic stroke. Int J Mol Sci2020;
21
82.
HerbertsCAKwaMSHermsenHP.Risk factors in the development of stem cell therapy. J Transl Med2011;
9: 29.
83.
SavitzSICramerSCWechslerL.Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials. Stroke2014;
45: 634–639.
84.
BoltzeJModoMMMaysRW, STEPS 4 Consortiumet al.
Stem cells as an emerging paradigm in stroke 4: Advancing and accelerating preclinical research. Stroke2019;
50: 3299–3306.
BenjaminEJBlahaMJChiuveSE, et al.
Heart disease and stroke statistics – 2017 update: a report from the American Heart Association. Circulation2017;
135: e146–e603.
87.
CampbellBCHillMDRubieraM, et al.
Safety and efficacy of solitaire stent thrombectomy: Individual patient data meta-analysis of randomized trials. Stroke2016;
47: 798–806.
88.
PowersWJDerdeynCPBillerJ, et al.
2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2015;
46: 3020–3035.
89.
SansingL. Pre-clinical translational stroke development: SPAN results and next steps. International stroke conference 2023. Dallas, TX, USA. 2023.
90.
LydenPDBosettiFDinizMA, et al.
The stroke preclinical assessment network: rationale, design, feasibility, and stage 1 results. Stroke2022;
53: 1802–1812.
91.
CrowleyMGLiskaMGBorlonganCV.Stem cell therapy for sequestering neuroinflammation in traumatic brain injury: an update on exosome-targeting to the spleen. J Neurosurg Sci2017;
61: 291–302.
92.
KinKYasuharaTKamedaM, et al.
Cell encapsulation enhances antidepressant effect of the mesenchymal stem cells and counteracts depressive-like behavior of treatment-resistant depressed rats. Mol Psychiatry2020;
25: 1202–1214.
93.
NguyenHAumDMashkouriS, et al.
Growth factor therapy sequesters inflammation in affording neuroprotection in cerebrovascular diseases. Expert Rev Neurother2016;
16: 915–926.
94.
KanekoYLeeJYTajiriN, et al.
Translating intracarotid artery transplantation of bone marrow-derived NCS-01 cells for ischemic stroke: behavioral and histological readouts and mechanistic insights into stem cell therapy. Stem Cells Transl Med2020;
9: 203–220.
95.
BrownJParkYJLeeJY, et al.
Bone marrow-derived NCS-01 cells advance a novel cell-based therapy for stroke. Int J Mol Sci2020;
21: 2845.
IslamRDrecunSVargaBV, et al.
Transplantation of human cortically-specified neuroepithelial progenitor cells leads to improved functional outcomes in a mouse model of stroke. Front Cell Neurosci2021;
15: 654290.
98.
NohJEOhSHParkIH, et al.
Intracerebral transplants of GMP-grade human umbilical cord-derived mesenchymal stromal cells effectively treat subacute-phase ischemic stroke in a rodent model. Front Cell Neurosci2020;
14: 546659.
99.
KiyoseRSasakiMKataoka-SasakiY, et al.
Intravenous infusion of mesenchymal stem cells enhances therapeutic efficacy of reperfusion therapy in cerebral ischemia. World Neurosurg2021;
149: e160–e169.
100.
TakemuraMSasakiMKataoka-SasakiY, et al.
Repeated intravenous infusion of mesenchymal stem cells for enhanced functional recovery in a rat model of chronic cerebral ischemia. J Neurosurg2021;
137: 402–411.
101.
ZhengJMaoXWangD, et al.
Preconditioned MSCs alleviate cerebral Ischemia-Reperfusion injury in rats by improving the neurological function and the inhibition of apoptosis. Brain Sci2022;
12: 631.
102.
TangWLvXHuangJ, et al.
Neuroprotective effect of stroke pretreated mesenchymal stem cells against cerebral iischemia/reperfusion injury in rats. World Neurosurg2022;
165: e1–e11.
MuirKWBultersDWillmotM, et al.
Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2). J Neurol Neurosurg Psychiatry2020;
91: 396–401.
105.
JaillardAHommelMMoisanA, et al.
Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke: a randomized clinical trial. Transl Stroke Res2020;
11: 910–923.
106.
LeeTKLuCYTsaiST, et al.
Complete restoration of motor function in acute cerebral stroke treated with allogeneic human umbilical cord blood monocytes: preliminary results of a phase I clinical trial. Cell Transplant2021;
30: 9636897211067447.
107.
ChiuTLBaskaranRTsaiST, et al.
Intracerebral transplantation of autologous adipose-derived stem cells for chronic ischemic stroke: a phase I study. J Tissue Eng Regen Med2022;
16: 3–13.
108.
BaakLMWagenaarNvan der AaNE, et al.
Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in The Netherlands (PASSIoN): a first-in-human, open-label intervention study. Lancet Neurol2022;
21: 528–536.
109.
LeeJChangWHChungJW, et al.
Efficacy of intravenous mesenchymal stem cells for motor recovery after ischemic stroke: a neuroimaging study. Stroke2022;
53: 20–28.
110.
LawZKTanHJChinSP, et al.
The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and efficacy. Cytotherapy2021;
23: 833–840.
111.
de Celis-RuizEFuentesBAlonso de LeciñanaM, et al.
Final results of allogeneic adipose tissue-derived mesenchymal stem cells in acute ischemic stroke (AMASCIS): a phase II, randomized, double-blind, placebo-controlled, single-center, pilot clinical trial. Cell Transplant2022;
31: 9636897221083863.
112.
ChungJWChangWHBangOY, et al.
Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke. Neurology2021;
96: e1012–e1023.
113.
LeeJSHongJMMoonGJ, et al.
A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells2010;
28: 1099–1106.
114.
LevyMLCrawfordJRDibN, et al.
Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke. Stroke2019;
50: 2835–2841.
115.
LiWShiLHuB, et al.
Mesenchymal stem cell-based therapy for stroke: Current understanding and challenges. Front Cell Neurosci2021;
15: 628940.
116.
Gonzales-PortilloGSSanbergPRFranzblauM, et al.
Mannitol-enhanced delivery of stem cells and their growth factors across the blood-brain barrier. Cell Transplant2014;
23: 531–539.
117.
SataniNCaiCGiridharK, et al.
World-wide efficacy of bone marrow derived mesenchymal stromal cells in preclinical ischemic stroke models: systematic review and meta-analysis. Front Neurol2019;
10: 405.
118.
CuiLLGolubczykDTolppanenAM, et al.
Cell therapy for ischemic stroke: are differences in preclinical and clinical study design responsible for the translational loss of efficacy?Ann Neurol2019;
86: 5–16.
119.
LiCZhaoHChengL, et al.
Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice. Cell Biosci2021;
11: 187.
120.
AcostaSATajiriNHooverJ, et al.
Intravenous bone marrow stem cell grafts preferentially migrate to spleen and abrogate chronic inflammation in stroke. Stroke2015;
46: 2616–2627.
121.
BorlonganCVLindJGDillon-CarterO, et al.
Intracerebral xenografts of mouse bone marrow cells in adult rats facilitate restoration of cerebral blood flow and blood-brain barrier. Brain Res2004;
1009: 26–33.
122.
YoshidaYTakagiTKuramotoY, et al.
Intravenous administration of human amniotic mesenchymal stem cells in the subacute phase of cerebral infarction in a mouse model ameliorates neurological disturbance by suppressing blood brain barrier disruption and apoptosis via immunomodulation. Cell Transplant2021;
30: 9636897211024183.
123.
KalladkaDSindenJPollockK, et al.
Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet2016;
388: 787–796.
124.
SudaSNitoCIharaM, J- REPAIR trial groupet al.
Randomised placebo-controlled multicentre trial to evaluate the efficacy and safety of JTR-161, allogeneic human dental pulp stem cells, in patients with acute ischaemic stRoke (J-REPAIR). BMJ Open2022;
12: e054269.
